Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GI Innovation, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT05824975
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Minnesota, Rochester, Minnesota, United States
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT05826015
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05821452
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, China
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05819892
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05809895
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05799612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT05798819
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT05800587
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 950
- Registration Number
- NCT05800015
- Locations
- 🇺🇸
Crosson Cancer Institute, Fullerton, California, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Aston Sci. Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT05794659
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.